Research Topics
| Kathleen LangSummaryAffiliation: Boston Health Economics Country: USA Publications
| Collaborators
|
Detail Information
Publications
Factors associated with improved survival among older colorectal cancer patients in the US: a population-based analysisKathleen Lang
Boston Health Economics, Inc, Waltham, USA
BMC Cancer 9:227. 2009..The purpose of this study was to estimate the relative impact of changes in demographics, stage at detection, treatment mix, and medical technology on 5-year survival among older colorectal cancer (CRC) patients...
Trends in healthcare utilization among older Americans with colorectal cancer: a retrospective database analysisKathleen Lang
Boston Health Economics, Inc, Waltham, MA, USA
BMC Health Serv Res 9:227. 2009..This retrospective cohort study evaluated healthcare resource use among US Medicare beneficiaries diagnosed with CRC between 1992 and 2002...
Trends in the treatment of acute myeloid leukaemia in the elderlyKathleen Lang
Boston Health Economics, Inc, Waltham, Massachusetts 02451, USA
Drugs Aging 22:943-55. 2005..Our findings can be used as a baseline against which the benefits of new therapies can be compared...
Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare dataKathleen Lang
Boston Health Economics, Inc, Waltham, Massachusetts 02451, USA
Clin Gastroenterol Hepatol 7:198-204. 2009..This study provides detailed estimates of lifetime and phase-specific colorectal cancer (CRC) treatment costs...
Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neckKathleen Lang
Boston Health Economics, Inc, 20 Fox Road, Waltham, MA 02451, USA
Arch Otolaryngol Head Neck Surg 135:582-8. 2009..To evaluate the incidence and costs of complications due to radiotherapy alone vs platinum-based chemoradiotherapy among patients diagnosed as having advanced squamous cell carcinoma of the head and neck (ASCCHN) from a payer perspective...
Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychoticsKathleen Lang
Boston Health Economics, Inc, Waltham, MA, USA
J Med Econ 14:217-26. 2011..To assess rates and predictors of medication nonadherence and hospitalization among patients with bipolar I disorder...
Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysisJoseph Menzin
Boston Health Economics, Inc, Waltham, Massachusetts, USA
Drugs Aging 21:737-46. 2004..To fill this void, our study uses population-based data to evaluate longer-term treatment patterns, outcomes and costs among elderly Medicare beneficiaries following their diagnosis of CML...
The outcomes and costs of acute myeloid leukemia among the elderlyJoseph Menzin
Boston Health Economics, Inc, 20 Fox Rd, Waltham, MA 02451, USA
Arch Intern Med 162:1597-603. 2002..The incidence of acute myeloid leukemia (AML) among the elderly can be expected to grow as the population continues to age. However, data on current treatment practices and costs for this form of cancer are sparse...
The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare dataKathleen Lang
Boston Health Economics Inc, Waltham, Mass, USA
Arch Otolaryngol Head Neck Surg 130:1269-75. 2004..CONCLUSION: These results suggest that the health economic burden of SCCHN is substantial, with costs that are comparable with or higher than those of other solid tumors...
Development of an interactive model of the burden of future coronary heart disease from an employer perspectiveKathleen Lang
Boston Health Economics, Inc, Waltham, MA 02451, USA
J Occup Environ Med 52:851-7. 2010..To create a computer-based model for employers to better understand the burden of coronary heart disease (CHD) to their organizations...
Medication adherence and hospitalization among patients with schizophrenia treated with antipsychoticsKathleen Lang
Boston Health Economics, Inc, Waltham, Massachusetts 02451, USA
Psychiatr Serv 61:1239-47. 2010..This analysis assessed rates of medication adherence and predictors of nonadherence and hospitalization among patients treated with long-acting injectable and oral antipsychotic therapies...
Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemiaKathleen Lang
Boston Health Economics, Inc, 20 Fox Road, Waltham, MA 02451, USA
Am J Health Syst Pharm 59:941-8. 2002..Gemtuzumab ozogamicin appeared to be associated with equivalent survival and fewer total days of hospitalization than conventional chemotherapy in adults with relapsed AML...
